PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

2004 re application of: Curtis, Rory A. J.

Application No.:

09/587,111

Group No.:

1646

June 2, 2000

Examiner:

Ulm, John D.

NOVEL MEMBERS OF THE CAPSAICIN/VANILLOID RECEPTOR

FAMILY OF PROTEINS AND USES THEREOF

Mail Stop Issue Fee **Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450

SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY, AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

[X] This replies to the Office Letter Dated <u>September 21, 2004</u> . [] A copy of the Office Letter is enclosed.	
[] A copy of the Office Letter is enclosed.	
IDENTIFICATION OF PERSON MAKING STATEMENT	
2. I, Mario Cloutier	
(type or print name of person signing below)	_
state the following:	
CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*	
I hereby certify that, on the date shown below, this correspondence is being:	
MAILING	
deposited with the United States Postal Service in an envelope addressed to Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	ŗ
37 C.F.R. SECTION 1.8(a) 37 C.F.R. SECTION 1.10*	
with sufficient postage as first class mail. as "Express Mail Post Office to Addressee" Mailing Label No. EV569762116US	
TRANSMISSION	
transmitted by facsimile to the Patent and Trademark Office.	
Sea Am	
Signature Signature	
Date: December 15, 2004 Sean Hunziker	

*WARNING:Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this

requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 4)

3. Submitted herewith is/are:

ITEMS BEING SUBMITTED

A. [x]	"Sequence	Listing(s)"	for the	nucleotide	and/or	amino	acid s	sequence(s)	in this	applic	ation.
	Each '	'Sequence L	isting" i	s assigned	a separa	ite ident	tifier a	is required i	n 37 C.I	F.R. S	ection

1.821(c) and 37 C.F.R. Sections 1.822 and 1.823.

- B. () An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 C.F.R. Section 1.821(d).
- C. (x) A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. Sections 1.821(e) and 1.824.
- D. () Please transfer to this application, in accordance with 37 C.F.R. Section 1.821(e), the computer readable copy(ies) from applicant's other application identified as follows:

In re application of:		
Application No.:	Group No.:	
Filed:	Examiner:	
For:		

The Computer readable form(s) of applicant's other application corresponds to the "Sequence Identifier(s)" of the application as follows:

Computer Readable Form	"Sequence Identifier"
(other application)	(this application)

E.	(x)	Α	statement	that	the	content	of	each	"Sequence	Listing"	submitted	and	each	computer
		re	adable copy	y are	the s	ame, as	req	uired i	n 37 C.F.R.	Section 1	1.821(g).			_

- () Because the statement is not made by a person registered to practice before the Office, the Statement is verified as required in 37 C.F.R. Section 1.821(b).
- F. () Because this submission is made in fulfilling the requirement under 37 C.F.R. Section 1.821(g), a statement that the submission includes no new matter.
 - [] Because the statement is not made by a person registered to practice before the Office, the statement is verified, as required in 37 C.F.R. Section 1.821(g).

STATEMENT THAT "SEQUENCE LISTING" AND COMPUTER READABLE COPY ARE THE SAME AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER

4. I hereby st	ate	
----------------	-----	--

- A. [x] Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate.
- B. [x] All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

EXTENSION OF TERM

- 5. The proceedings herein are for a patent application and the provisions of 37 C.F.R. Section 1.136 apply.
 - (a) [] Applicant petitions for an extension of time under 37 C.F.R. Section 1.136 (fees: 37 C.F.R. Section 1.17(a)(1)-(4)) for the total number of months checked below:

Extension (months)	Fee for other than small entity	Fee for small entity
() one month() two months() three months() four months	\$ 110.00 \$ 390.00 \$ 890.00 \$1,390.00	\$ 55.00 \$ 195.00 \$ 445.00 \$ 695.00
		Fee \$0.00

If an additional extension of time is required, please consider this a petition therefor.

l	J	An extension for	months has already been secured, and the fee paid therefor of
	_	\$0.00	is deducted from the total fee due for the total months of extension
		now requested.	

Extension fee due with this request \$0.00

OR

(b) (x) Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.

	PEE FAINLENI
6. [] Attached is a check in the sum	of\$
() Charge Account No. 501668 A duplicate of this transmittal	
	FEE DEFICIENCY
B. (x) If any additional extension and	d/or fee is required, charge Account No. 501668
December 15, 2004	MILLENNIUM PHARMACEUTICALS, INC.
	By Mario Cloutier Limited Recognition under 37 C.F.R. §10.9(b) 40 Landsdowne Street Cambridge, MA 02139 Telephone – (617) 577-3522 Facsimile – (617) 551-8820